

Edgar Filing: NOVARTIS AG - Form 6-K

NOVARTIS AG
Form 6-K
January 09, 2004

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated January 9, 2004
(Commission File No. 1-15024)

Novartis AG
(Name of Registrant)

Lichtstrasse 35
4056 Basel
Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:

Form 20-F: ☒ Form 40-F: ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):

Yes: ☐ No: ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):

Yes: ☐ No: ☒

Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes: ☐ No: ☒

Enclosure: Invitation to Participate in Novartis' Full Year Results 2003
Presentation.

Edgar Filing: NOVARTIS AG - Form 6-K

Investor Relations

Novartis International AG
CH-4002 Basel
Switzerland

[GRAPHIC OMITTED]

Novartis Corporation
608 Fifth Avenue
New York, NY 10020
USA

-SAVE THE DATE-

Novartis' Full Year Results 2003 Presentation

to be held

in Zurich, Switzerland

on

Thursday, January 22, 2004

Door opening at 13.30, start at 14:00

#

Novartis Global Investor Relations

Karen J. Huebscher, Ph.D. +41 61 324 84 33

International office

Nafida Bendali +41 61 324 35 14

Katharina Furrer +41 61 324 53 16

Silke Zentner +41 61 324 86 12

e-mail: investor.relations@group.novartis.com

Fax: +41 61 324 84 44
www.novartis.com

North American office

Alex Kelly +1 212 830 24 45

John Menditto +1 212 830 24 44

Sabine Moravi +1 212 830 24 56

Jill Pozarek +1 212 830 24 45

e-mail: investor.relations@group.novarti

Fax: +1 212 830 24 05
www.novartis.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

Edgar Filing: NOVARTIS AG - Form 6-K

Novartis AG has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NOVARTIS AG

Date: January 9, 2004

By: /s/ MALCOLM CHEETHAM

Name: Malcolm Cheetham

Title: Head Group Financial Reporting
and Accounting